TCT 2017: Boston Scientific reveals presentations at conference

674
Boston Scientific’s Watchman

Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). For example, on 2 November, data for the Watchman left atrial appendage closure device will be featured in a late-breaking clinical trial session. It will highlight the five-year outcomes from PREVAIL, a randomised trial examining left atrial appendage closure vs. medical therapy in patients with non-valvular atrial fibrillation.

Other presentations include five-year follow-up data from the continued access to PROTECT AF (CAP) registry, which is related to long-term event rates for left atrial appendage closure with the Watchman device, and a subanalysis from the PLATINUM Diversity study that will address predictors of increased risk for cardiac events following percutaneous coronary intervention in minority women.

Ian Meredith

Ian Meredith, executive vice president and global chief medical officer, Boston Scientific, comments: “We look forward to continuing the important dialogue around the Watchman device as an alternative option to long-term warfarin therapy for patients with non-valvular atrial fibrillation who are seeking another treatment to reduce their risk of stroke. Additionally, presentations around our drug-eluting innovations, structural heart technologies and our therapeutic options addressing chronic total occlusions will help provide clinicians with insights that can be applied to their practice of treating coronary and peripheral artery disease.”

The data include:

30 October

  • Watchman device: Budget impact of stroke reduction strategies in atrial fibrillation: Medicare and patient perspectives. 10.30am in the Moderated Posters 8 area, Exhibit Hall, Exhibit Level
  • Promus Premier drug-eluting coronary stent system: Clinical, social, and behavioural predictors of the increased risk of cardiac events after PCI in minority women: A subanalysis of the PLATINUM Diversity study. 10.30am. in the Moderated Posters 1 area, Exhibit Hall, Exhibit Level
  • Lotus aortic valve system: Importance of contrast aortography with Lotus transcatheter aortic valve replacement—A post-hoc analysis from the RESPOND Post-market study. 3:48pm in the Moderated Posters 7 area, Exhibit Hall, Exhibit Level.

31  October

  • ACURATE neo aortic valve system: Transcatheter Aortic Valve Replacement with the ACURATE NEO – One Year Results: 9.54am in the Moderated Posters 2 area, Exhibit Hall, Exhibit Level.
  • Lotus aortic valve system: Four-year outcomes with the fully repositionable and retrievable Lotus transcatheter aortic valve: Results from the REPRISE II Study: 10.30am in the Moderated Posters 7 area, Exhibit Hall, Exhibit Level.
  • ELUVIA drug-eluting vascular stent system: Biomechanics and drug elution in arterial response to peripheral stents: A comparative study of 3 contemporary stents in balloon-predilated femoral arteries of familial hypercholesterolemic swine: 12.15pm in Room 503, Meeting Room Level.
  • Watchman: Five-Year outcomes of left atrial appendage closure: Final results of the continued access to PROTECT AF (CAP) registry: 1.15pm in Room 504, Meeting Room Level.

2 November

  • Watchman device: PREVAIL: 5-year outcomes from a randomised trial of left atrial appendage closure vs medical therapy in patients with non-valvular atrial fibrillation. Late Breaking Clinical Trial session in the Main Arena IV.

LEAVE A REPLY